| From : | a.turdziladze@caucasus.net |
| To : | Ahmad Hashem <ahmad@hashem.net>; Alexander Nodia <anodia@hssp.org.ge>; Ketevan Tatoshvili <ktatoshvili@hssp.org.ge>; amy@mdinformatics.com |
| Subject : | RE: Drug Database fields |
| Cc : | Terry <Terry@mdinformatics.com>; Tamta Kobakhidze <tkobakhidze@hssp.org.ge> |
| Received On : | 06.04.2012 10:20 |
I also would like to ask Ahmad,
Wednesday any time, Thursday late not 19;00
Could we set for example Wednesday 19;00??
Thanks,
Alexander
From: Ahmad Hashem
[mailto:ahmad@hashem.net]
Sent: Friday, April 06, 2012 3:32 AM
To: 'Alexander Nodia'; 'Ketevan Tatoshvili'; amy@mdinformatics.com;
'Aleko'
Cc: 'Terry'; 'Tamta Kobakhidze'
Subject: RE: Drug Database fields
Dear all,
I have a board meeting at this time so I can’t attend. I would
be happy to join the call if it is Wednesday any time, or Thursday at 10pm
Tbilisi time.
Regards,
Ahmad
From: Alexander Nodia
[mailto:anodia@hssp.org.ge]
Sent: Thursday, April 05, 2012 5:10 PM
To: Ketevan Tatoshvili; amy@mdinformatics.com; Aleko
Cc: Terry; Ahmad Hashem; Tamta Kobakhidze
Subject: RE: Drug Database fields
Thanks Keti
Suggested date and time works for me..
Best regards
Alexander Nodia
Senior Expert in Health Information System
USAID Health System Strenghtening Project
1B, Budapest Street, 5th floor
Tbilisi 0160, Georgia
Tel. (995 32) 388 733, 388 734 ext. 106
Fax: (995 32) 388 735
From: Ketevan Tatoshvili
Sent: Thursday, April 05, 2012 1:57 PM
To: amy@mdinformatics.com; Alexander Nodia; Aleko
Cc: Terry; Ahmad Hashem; Tamta Kobakhidze
Subject: RE: Drug Database fields
Thanks Amy,
Yes “Yellow Fields” are provided by Tina. Today, I have whole
day already booked, so will work on field definitions tomorrow and send it
right away.
Agree with the DUN system. Let us discuss the rest and share our
feedback during the Skype call. I think having a conf. call will be very
useful, no matter how far we are advanced in our research. Please note, that
Monday and Friday are public holidays (April 9 and 13), so maybe we do it on Thursday,
April 12 @ 19:00 Georgian time.
Amy, local colleagues: can you please confirm if
suggested time works for you or not?
Amy: do we know when to expect the specifications for E-prescribing
part?
Thanks again and again for a very productive work!
Best,
Keti
From: Amy Sletta [mailto:amy@mdinformatics.com]
Sent: Thursday, April 05, 2012 8:15 AM
To: Ketevan Tatoshvili; Alexander Nodia; Aleko
Cc: Terry; Ahmad Hashem
Subject: RE: Drug Database fields
Keti,
I have incorporated your comments into the attached document and expanded the
document to include the fields to capture the actual drug registration in
Section II. This is a very rough draft. There are items
highlighted in yellow and red.
Yellow fields are those proposed by the local Georgian expert (Is this Tina?) -
if you can provide definitions for these fields, we can map them to the list of
fields or add them if they are not already included.
Red fields are those that we (MDi) need to research more and/or to think
about how this would best work in Georgia.
Some additional comments:
The DUNS number could be an optional number that is only captured if the
business has registered with Dun and Bradstreet. If available it could
aid in further identification especially of non-Georgian
businesses.
We would envision that both manufacturers and importers would be stored in the
same database but with different values for the field type of operation(s) performed at each
entity. There
may need to be a way to link the Entity or overall Business Organization with
their associated importers or suborganizations - we should probably discuss
this situation further and then modify the Drug Database fields document as
needed.
The pdf files containing indication,
contraindication, drug interaction and so on will be useful but are probably
not in the format required to perform drug/drug, drug/allergy etc... checking
in e-Prescribing. One of our next tasks may be to price out the
Drug Information databases like First Data Bank, Multum and Gold Standard that
are embedded into e-Prescribing systems to perform these clinical
checks.
Please let us know if you have any questions or would like additional
information or clarification in any area. It may be useful to schedule a
Skype call for next week (when Ahmad is back from Albania) to review this
document and any areas requiring more discussion. Thank you
Amy
Sletta
MD Informatics, LLC
cell 435-659-1477
fax 925-380-5166
amy@mdinformatics.com
From: "Ketevan Tatoshvili" <ktatoshvili@hssp.org.ge>
Sent: Sunday, April 01, 2012 3:31 AM
To: "amy@mdinformatics.com"
<amy@mdinformatics.com>,
"Alexander Nodia" <anodia@hssp.org.ge>,
"Aleko" <a.turdziladze@caucasus.net>
Subject: RE: Drug Database fields
Hi all,
Thank you for yet another comprehensive review of the issue. The
document includes lots of details that we’ll discuss in coming week, but before
here’s my feedback, some comments and news from the drug regulation dep.
Answer to your comments (in the doc): 1.
The decision re GeNDC had not been made yet. Will keep you posted on any
progress. 2. That’s absolutely correct and it is the ultimate goal. Currently
there is a negotiation going around with the Public Registry. Ako and team
studied all the potential information/data what we need and what is available
in Public registry database. So, the conclusion is that all this information is
retrievable/available and we just need to be granted a permission. 3. Ako will probably answer
the 3rd comment
Other comments: Agree that Data Universal
Numbering System could be of a lot of help here. We have also looked at this
system, but originally we were searching for the ways of including this into
the GeNDC. Shortly, establishing connection with DUN system is important, especially
helpful for imported products. Probably, we need to check the possibility and
ways of getting this information.
Company specific information re local manufactures will be
derived from the database we are creating now. Let’s us see how we can make it
more comprehensive. Ideally the information re importers should be derived from
similar database and I’ll check in with the drug regulator where they stand in
this regard and try to get importers’ registry, if available.
Meeting with the drug regulation dep.: There
are no specific requirements on their end regarding the drug database. The only
requirement is to include packaging and labeling information (images) and a
possibility to automatically update the public site of registered drugs from
this drug database. In fact both requirements are already included in our
agenda.
Moreover, I’ve learned that they started uploading drug
related clinical/scientific information (PDF files)into the public site, such
as: indication, contraindication, drug interaction and so on. However, this
valid only for drugs registered in the frame of National (complete)
registration procedure. Having this type of resource will help us a lot with
e-prescribing.
That’s all for now. Looking forward to further information from
you, Thanks again!!
K
From: Amy Sletta [mailto:amy@mdinformatics.com]
Sent: Saturday, March 31, 2012 9:15 PM
To: Ketevan Tatoshvili; Alexander Nodia; Aleko
Cc: Terry; Ahmad Hashem
Subject: Drug Database fields
All,
Please find the first section of recommended fields for the Drug
database. This section contains fields used for the Registration of the
Entity/Organization that will be manufactoring, importing etc... the
drugs. We are continuing to work on the fields for the registration of
the actual drug and will send you those fields no later than Wednesday of the
coming week.
Please let us know if you have any questions or would like additional
information. Thank you
Amy
Sletta
MD Informatics, LLC
cell 435-659-1477
fax 925-380-5166
amy@mdinformatics.com
This message may contain
privileged and confidential information intended solely for the addressee.
Please do not read, disseminate or copy it unless you are the intended
recipient. If this message has been received in error, we kindly ask that you
notify the sender immediately by return email and delete all copies of the
message from your system. Thank you.
This message may contain privileged and confidential information
intended solely for the addressee. Please do not read, disseminate or copy it
unless you are the intended recipient. If this message has been received in
error, we kindly ask that you notify the sender immediately by return email and
delete all copies of the message from your system. Thank you.